Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q4 FY25 Earnings Presentation
18 slides from Zydus Lifesciences's earnings presentation, May 20, 2025
Slide 1: Exchange filing cover letter for Investor Presentation
May 20, 2025 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please find
Slide 2: Earnings Presentation: Q4 & Full Year FY25
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation: Q4 & Full Year FY25 20th May, 2025 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q4 FY25: At a Glance
Q4 FY25: At a Glance Revenues from Highlights of Q4 FY25 R&D Operations ❑ Total revenues grew 18% YoY. Rs. 65,279 mn Rs. 4,799 mn ❑ India branded formulations business posted double-digit growth and 18% YoY 7.4% of revenues outpaced the market growth. Net Profit ex. ❑ Consumer Wellness business deli
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 70.9% 69.9% 74.0% 68.1% 72.7% 2,32,415 48,308 1,69,035 65,279 55,338 1,95,474 39,223 1,33,192 52,691 36,857 Q4FY24 Q3FY25 Q4FY25 FY24 FY25 Q4FY24 Q3FY25 Q4FY25 FY24 FY25 Total R&D (Rs. mn) and % to Revenues
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 13,905 47,451 3,202 12,140 2,907 11,823 38,737 10,235 8,628 2,126 Q4FY24 Q3FY25 Q4FY25 FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25 FY24 FY25 Net Cash (Rs. mn) Net Working Capital* (Rs. mn) 48,836 71,427 65,354 62,596 60,585 56,629
Slide 7: India Formulations business
India Formulations business Sustained market outperformance led by strong volume uptake Highlights for the quarter Q4 FY25 Revenue ▪ Branded business grew faster than the market with Contribution 11% YoY growth, driven by high uptick in pillar brands and innovation products. ▪ Secondary sales grew f
Slide 8: Consumer Wellness
Consumer Wellness Strong volume uptake driven by robust demand across categories Highlights for the quarter Q4 FY25 Revenue Contribution ▪ Growth was largely driven by strong 13% volume growth. ▪ Personal care segment witnessed strong consumer 14% traction and achieved robust double-digit growth. ▪
Slide 9: US Formulations business
US Formulations business Base business volume expansion and new launches led to strong growth Highlights for the quarter Q4 FY25 Revenue Q4 FY25 Revenue Contribution Contribution ▪ Base business grew sequentially every quarter through the year driven by volume expansion and new launches. ▪ Launched
Slide 10: International Markets Formulations business
International Markets Formulations business Strong growth on the back of resilient demand across markets Highlights for the quarter Q4 FY25 Revenue Q4 FY25 Revenue Contribution Contribution ▪ Sustained the growth momentum with a strong demand led growth across geographies. ▪ Focused on expanding the
Slide 11: Updates on Innovation (1/2)
Updates on Innovation (1/2) NCE: Saroglitazar Magnesium • Data monitoring and follow-up is going on post the completion of patient recruitment for Phase II(b)/ III clinical trials for PBC indication and Phase II(b) clinical trials MASH indication for the US market. NCE: Usnoflast • Received the USFD
Slide 12: Updates on Innovation (2/2)
Updates on Innovation (2/2) Specialty Initiatives • Entered into an exclusive licensing, supply and commercialization agreement with Zhuhai Beihai Biotech Co., Ltd for BEIZRAY, which is an Albumin Solubilized Docetaxel Injection, a 505(B)(2) product for the US market. BEIZRAY, is the first clinicall
Slide 13: Other Updates
Other Updates • Forayed into Medtech space by entering into a share purchase agreement to acquire a majority stake in Amplitude Surgical SA, France. • The proposed acquisition shall act as a platform to x Zy ’g b MedTech strategy and a natural extension for the Company having a proven track record i
Slide 14: Zydus at a Glance
Zydus at a Glance ~$2.75 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 8 R&D Centers For NCE, APIs, Generics, Vaccines Biosimilars and Wellness products Among 1st Revenues from India Approved product for >35% In >55% of product Geography (Formulations Top 3 families mar
Slide 15: ESG Highlights
ESG Highlights zyd~ Dedicated To Life ESG Performance ESG Ratings Period 2022 2023 2024 ... Climate Change @f 45% reduction in GHG Intensity by 2030 •• - - ~ (GHG Emissions) ~2/3 of target achieved. : S&P Global II @f Net Carbon Neutral by 2035 ~ ~40% of renewable energy in the total energy mix . .
Slide 16: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q4 Q4 YoY Q3 QoQ YoY Rs. mn FY25 FY24 FY25 FY24 gr. FY25 gr. gr. Total Income from Ops. 65,279 55,338 18.0% 52,691 23.9% 2,32,415 1,95,474 18.9% Gross Contribution (GC) 48,308 39,223 23.2% 36,857 31.1% 1,69,035 1,33,192 26.9% Gross Margin % 74.0% 70.9% 6
Slide 17: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q4 Q4 YoY YoY Rs. mn FY25 FY24 FY25 FY24 gr. % gr. % A. On operating transactions (above EBITDA line) 504 -57 983.3% -1,451 -864 -68.0% a. Included in COGS 110 -4 2815% 183 -54 441.5% b. Part of other operating expenses (shown separately) 394 -53 843% -1,634 -81
Slide 18: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C